{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:54:30Z","timestamp":1789505670862,"version":"build-2803163510"},"reference-count":12,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2021,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To analyze the efficacy, safety, and accessibility of netarsudil 0.02% in patients with glaucoma (suspect, open or closed) at a safety-net academic medical center, Boston Medical Center (BMC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Retrospective chart review of patients prescribed netarsudil 0.02% for uncontrolled glaucoma at BMC between December 2017 and September 2019. Outcome measures included change in intraocular pressure (IOP) from baseline and evaluation of adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>One hundred thirty patients (60% severe stage) were analyzed. The IOP reduction from baseline was about 3\u2009mmHg. Fifty-four patients (42%) experienced an AE (eg, conjunctival hyperemia). Thirty-eight patients (29%) started netarsudil 0.02% in lieu of laser or surgery. Ninety-nine patients (71%) required prior authorization for insurance coverage of netarsudil 0.02%. Ten patients (7%) were unable to obtain netarsudil 0.02% due to issues with insurance coverage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Netarsudil 0.02% yielded significant IOP reduction in our cohort, however, to a smaller degree compared with prior studies that bore equivocal IOP reduction regardless of baseline IOP. Conjunctival hyperemia was the most common AE. In a limited number of patients, netarsudil 0.02% was not covered by insurance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2020.0112","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T15:09:42Z","timestamp":1620918582000},"page":"338-342","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Real-World Clinical Impact of Netarsudil 0.02% at an Urban Safety-Net Hospital"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2065-4568","authenticated-orcid":false,"given":"Gabrielle","family":"Fridman","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Boston Medical Center\/Boston University School of Medicine, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Sadlak","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Boston Medical Center\/Boston University School of Medicine, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Eliassi-Rad","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Boston Medical Center\/Boston University School of Medicine, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manishi A.","family":"Desai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Boston Medical Center\/Boston University School of Medicine, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,7,28]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.03.002"},{"key":"e_1_3_3_3_2","first-page":"186","article-title":"Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure","author":"Serle J.","year":"2017","unstructured":"Serle J., , Katz L., , McLaurin E., et al. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure. Am. J. Ophthalmol. 186, 2017.","journal-title":"Am. J. Ophthalmol"},{"key":"e_1_3_3_4_2","first-page":"S279","article-title":"Current therapeutic options and treatments in development for the management of primary open-angle glaucoma","volume":"23","author":"Liebmann J.M.","year":"2017","unstructured":"Liebmann J.M., , and Lee J.K. Current therapeutic options and treatments in development for the management of primary open-angle glaucoma. Am. J. Manag. Care, 23(15 Suppl.):S279\u2013S292, 2017.","journal-title":"Am. J. Manag. Care"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2017.0023"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-019-0671-0"},{"key":"e_1_3_3_7_2","unstructured":"Tripathy K. and Geetha R. Latanoprost. In: StatPearls. Treasure Island FL: StatPearls Publishing; 2020. www.ncbi.nlm.nih.gov\/books\/NBK540978\/ Accessed December8 2020."},{"key":"e_1_3_3_8_2","unstructured":"Barnes J. and Moshirfar M. Timolol. In: StatPearls. Treasure Island FL: StatPearls Publishing; 2020. www.ncbi.nlm.nih.gov\/books\/NBK545176\/ Accessed December8 2020."},{"key":"e_1_3_3_9_2","unstructured":"Snapshot. https:\/\/rhopressa.com\/ Accessed March29 2020."},{"key":"e_1_3_3_10_2","unstructured":"ICD-10 Glaucoma Reference Guide. 2015. https:\/\/www.aao.org\/Assets\/5adb14a6-7e5d-42ea-af51-3db772c4b0c2\/636713219263270000\/bc-2568-update-icd-10-quick-reference-guides-glaucoma-final-v2-color-pdf?inline=1 Accessed January1 2021."},{"key":"e_1_3_3_11_2","unstructured":"Rhopressa (netarsudil) Ophthalmic Solution. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/208254Orig1s000TOC.cfm Accessed December8 2020."},{"key":"e_1_3_3_12_2","first-page":"460","article-title":"and Toronto Area Glaucoma Society","volume":"19","author":"Birt C.M.","year":"2010","unstructured":"Birt C.M., , Buys Y.M., , Ahmed I.I., , Trope G.E.; and Toronto Area Glaucoma Society. Prostaglandin efficacy and safety study undertaken by race (the PRESSURE study). J. Glaucoma 19:460\u2013467, 2010.","journal-title":"Prostaglandin efficacy and safety study undertaken by race (the PRESSURE study)"},{"key":"e_1_3_3_13_2","first-page":"2393","article-title":"The efficacy and safety profile of netarsudil 0.02% in glaucoma treatment: real-world outcomes","volume":"60","author":"Ustaoglu M.","year":"2019","unstructured":"Ustaoglu M., , Shiuey E., , Sanvicente C., et al. The efficacy and safety profile of netarsudil 0.02% in glaucoma treatment: real-world outcomes. Invest. Ophthalmol. Vis. Sci. 60:2393\u20132393, 2019.","journal-title":"Invest. Ophthalmol. Vis. Sci"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2020.0112","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2020.0112","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2020.0112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:44:19Z","timestamp":1777646659000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2020.0112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,28]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,8,1]]}},"alternative-id":["10.1089\/jop.2020.0112"],"URL":"https:\/\/doi.org\/10.1089\/jop.2020.0112","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,28]]}}}